Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-H9 in Adult Growth Hormone Deficiency
NCT02946606Phase 2Completed
- Sponsor
- Genexine
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eftansomatropin alfa in adult growth hormone deficiency (AGHD), sponsored by Genexine. Primary endpoint: Change in insulin-like growth factor-1 levels at 12 weeks. Started Jan 2015; status: completed.
02
Drugs
eftansomatropin alfa
03
Conditions
adult growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on NCT02946606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02946606.